22:17 , May 24, 2019 |  BC Extra  |  Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

Cytokine mimics permit control of dimer receptor signaling  David Baker and Christopher Garcia's University of Washington-Stanford University team has created cytokine mimetics -- symmetric compounds for tunable control of cytokine receptor signaling. In a proof-of-concept...
19:17 , May 15, 2019 |  BC Innovations  |  Translation in Brief

Optimizing base editors to reduce RNA edits

Two Beam co-founders, Keith Joung and David Liu, have separately optimized CRISPR-guided base editors to reduce off-target RNA editing, which, along with unwanted DNA edits, is an emerging problem for the gene engineering tools. Beam...
01:01 , May 7, 2019 |  BC Innovations  |  Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
19:25 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

ADORA2A identified as a thrombosis target

DISEASE CATEGORY: Cardiovascular INDICATION: Thrombosis Cell culture and mouse studies suggest agonizing ADORA2A could help treat thrombosis. In primary human and mouse neutrophils treated with IgG from patients with antiphospholipid syndrome (APS), which is associated...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
17:30 , Mar 8, 2019 |  BC Week In Review  |  Company News

J&J gets option to AdoRx's adenosine receptor antagonists for lung cancer

AdoRx granted Johnson & Johnson an exclusive option to research, develop and commercialize adenosine receptor antagonists to treat lung cancer. AdoRx Therapeutics Ltd. (Edinburgh, U.K.) and Johnson & Johnson (NYSE:JNJ) will partner on drug discovery...
14:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

Blocking B cell vesicles to enhance chemotherapy

Blocking extracellular vesicles derived from B cells could offer a new therapeutic avenue to enhance the efficacy of chemotherapy for cancer, according to a Zhejiang University study. Chemotherapy reduces antitumor immunity by inducing systemic immunosuppression....
14:04 , Feb 12, 2019 |  BC Innovations  |  Translation in Brief

Storm’s RNA modification software

Storm Therapeutics Ltd. has created an algorithm to extend the use of mass spectrometric data to RNA epigenetics. Making it open source, the company plans to put the algorithm in as many hands as possible...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
01:04 , Jan 11, 2019 |  BioCentury  |  Finance

Exscientia looks inward

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build...